Glazer Capital LLC Makes New $768,000 Investment in Boston Scientific Corporation $BSX

Posted by Stanley Muller on Aug 28th, 2026

Boston Scientific logo Glazer Capital LLC bought a new position in Boston Scientific Corporation (NYSE:BSX – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 17,999 shares of the medical equipment provider’s stock, valued at approximately $768,000.

Several other hedge funds also recently made changes to their positions in BSX. BlackRock Inc. purchased a new position in Boston Scientific during the 2nd quarter valued at about $5,534,781,000. State Street Corp grew its holdings in Boston Scientific by 1.4% in the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after purchasing an additional 920,495 shares during the period. Primecap Management Co. CA bought a new position in shares of Boston Scientific during the second quarter valued at approximately $2,156,233,000. Capital World Investors increased its stake in shares of Boston Scientific by 1.9% during the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after purchasing an additional 502,627 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Boston Scientific during the fourth quarter valued at approximately $2,199,395,000. 89.07% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Needham & Company LLC cut their price target on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research note on Wednesday, July 8th. Wolfe Research cut Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th. Royal Bank Of Canada cut their target price on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, July 30th. Zacks Research downgraded Boston Scientific from a “hold” rating to a “strong sell” rating in a report on Friday, June 5th. Finally, Oppenheimer lowered their price target on Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a research report on Monday, July 27th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

Check Out Our Latest Research Report on Boston Scientific

Boston Scientific Stock Performance

BSX stock opened at $46.64 on Friday. The stock’s 50 day simple moving average is $46.53 and its 200 day simple moving average is $56.72. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a 12-month low of $42.20 and a 12-month high of $109.50. The stock has a market capitalization of $67.59 billion, a PE ratio of 18.88, a price-to-earnings-growth ratio of 1.05 and a beta of 0.56.

Boston Scientific (NYSE:BSX – Get Free Report) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts forecast that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has authorized a share repurchase plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its shares are undervalued.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

Positive Sentiment: Director Susan E. Morano reportedly purchased additional Boston Scientific shares, signaling confidence from an insider while the stock is near its recent lows. Top Boston Scientific Insider Makes Bold New Share Grab
Neutral Sentiment: The company’s latest quarterly results had been stronger than expected, with adjusted EPS and revenue exceeding consensus estimates and revenue rising year over year. However, that earnings momentum may provide limited near-term support while the cyber incident remains unresolved.
Negative Sentiment: Boston Scientific said the cyberattack disrupted information systems used to process customer orders and ship products worldwide. The company is working to restore access, but the timing of a full recovery remains unclear, raising the risk of shipment delays, lost sales, remediation costs and weaker near-term results. Boston Scientific hit by cyberattack, global operations affected
Negative Sentiment: The cybersecurity disruption comes alongside reports of a cardiac-device recall, increasing investor concerns about operational reliability, regulatory exposure and pressure on Boston Scientific’s growth outlook. The company has not yet quantified the financial impact of either issue. Boston Scientific hit with cardiac device recall

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney bought 186,240 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director David C. Habiger purchased 2,100 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were bought at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the acquisition, the director owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders acquired 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is owned by insiders.

About Boston Scientific

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.